Botta, C.; Colombo, G.L.; Di Matteo, S.; Martinotti, C.; Fogliati, E.L.; Bruno, G.M.; Novelli, G.; Di Virgilio, R.; Veggia, B.; Galimberti, S.
Cost-Effectiveness of Elranatamab Versus Teclistamab for the Management of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in Italy. Cancers 2026, 18, 1070.
https://doi.org/10.3390/cancers18071070
AMA Style
Botta C, Colombo GL, Di Matteo S, Martinotti C, Fogliati EL, Bruno GM, Novelli G, Di Virgilio R, Veggia B, Galimberti S.
Cost-Effectiveness of Elranatamab Versus Teclistamab for the Management of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in Italy. Cancers. 2026; 18(7):1070.
https://doi.org/10.3390/cancers18071070
Chicago/Turabian Style
Botta, Cirino, Giorgio Lorenzo Colombo, Sergio Di Matteo, Chiara Martinotti, Emma Lucia Fogliati, Giacomo Matteo Bruno, Giuseppe Novelli, Roberto Di Virgilio, Barbara Veggia, and Sara Galimberti.
2026. "Cost-Effectiveness of Elranatamab Versus Teclistamab for the Management of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in Italy" Cancers 18, no. 7: 1070.
https://doi.org/10.3390/cancers18071070
APA Style
Botta, C., Colombo, G. L., Di Matteo, S., Martinotti, C., Fogliati, E. L., Bruno, G. M., Novelli, G., Di Virgilio, R., Veggia, B., & Galimberti, S.
(2026). Cost-Effectiveness of Elranatamab Versus Teclistamab for the Management of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in Italy. Cancers, 18(7), 1070.
https://doi.org/10.3390/cancers18071070
